SCHEMBL4171230

SCHEMBL4171230

CC1=C(C=Cc2cccc(CC(C)C(=O)O)c2)C(C)(C)CCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.49
RXRA P19793 9/20 0.46
RXRB P28702 4/20 0.46
RXRG P48443 4/20 0.46
RARA P10276 7/20 0.44
RARB P10826 7/20 0.44
RARG P13631 7/20 0.44
HAO1 Q9UJM8 1/20 0.44
PLA2G2A P14555 1/20 0.41
PLA2G4A P47712 1/20 0.41
ALDH1A1 P00352 6/20 0.39
MAPT P10636 5/20 0.39
PTGS1 P23219 3/20 0.39
RORC P51449 2/20 0.39
CYP3A4 P08684 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
MAPK1 P28482 2/20 0.39
HTR2B P41595 2/20 0.39
BLM P54132 2/20 0.39
HIF1A Q16665 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4171227 1.00 CYP1A2 (0.49) CYP1A2RXRARXRBRXRGRARA
SCHEMBL8801629 0.89 CYP1A2 (0.44) CYP1A2RXRARXRBRXRGRARA
SCHEMBL8802428 0.85 CYP1A2 (0.42) CYP1A2RXRARXRBRXRGRARA
SCHEMBL4175695 0.83 CYP1A2 (0.40) CYP1A2RXRARXRBRXRGRARA
SCHEMBL4175698 0.83 CYP1A2 (0.40) CYP1A2RXRARXRBRXRGRARA
SCHEMBL8803747 0.82 CYP1A2 (0.41) CYP1A2RXRARXRBRXRGRARA
SCHEMBL4174909 0.82 CYP1A2 (0.41) CYP1A2RXRARXRBRXRGRARA
SCHEMBL4174913 0.82 CYP1A2 (0.41) CYP1A2RXRARXRBRXRGRARA
SCHEMBL4171195 0.79 CYP1A2 (0.45) CYP1A2RXRARXRBRXRGRARA
SCHEMBL4171193 0.79 CYP1A2 (0.45) CYP1A2RXRARXRBRXRGRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10201545-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2019-02-12 US disclosed
US-9421210-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-08-23 US disclosed
US-20160193160-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. 2016-07-07 US disclosed
US-9314467-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-04-19 US disclosed
US-20150238497-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2015-08-27 US disclosed
US-20150166494-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. 2015-06-18 US disclosed
US-20150166495-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. 2015-06-18 US disclosed
US-8653142-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2014-02-18 US disclosed
US-20130253064-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2013-09-26 US disclosed
US-8420863-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA, INC. (US) 2013-04-16 US disclosed
US-20120129860-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2012-05-24 US disclosed
EP-2076124-A2 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS Acucela, Inc. (US) 2009-07-08 EP disclosed
US-20090170841-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. (US) 2009-07-02 US disclosed
WO-2008131368-A2 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166495-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885
US-20150166494-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885
US-20120129860-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885
US-20130253064-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885
US-20150238497-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885
US-20160193160-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885
US-10201545-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885
US-20090170841-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 CYP1A2 4246/4885RXRA 1373/4885RXRB 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.